





	<ul style="list-style-type: none"> Established in 2000; holding company of a healthcare group headquartered in Hong Kong. Focus on researching, developing, manufacturing and selling pharmaceuticals, and health oriented consumer products primarily in the China market. Listed on the Alternative Market of London Stock Exchange in 2006. A wholly-owned subsidiary of Hutchison Whampoa Ltd. ("HWL"), an international corporation listed on the Main Board of the Hong Kong Stock Exchange
	<p>China Healthcare Division – Established, stable, and diversified China pharmaceuticals operation with exciting growth prospects based on its market leading products and the rapid expansion of the pharmaceutical industry in China. Visit: http://www.chi-med.com/eng/business/healthcare.htm</p>
	<p>Drug R&D Division (Hutchison MediPharma Limited, HMP) – Investment over past ten years in establishing China's leading end-to-end oncology and immunology drug R&D operation. Visit: http://www.chi-med.com/eng/business/drugs.htm</p>
	<p>Consumer Products Division – This Division is an extension of our China operation which enables Chi-Med to capture part of the growing consumer trend towards healthy living and to capitalise on the considerable consumer products synergies with the broader HWL group. Visit: http://www.chi-med.com/eng/business/products.htm</p>

About Hutchison MediPharma Limited (HMP)

	<p>HMP's internal botanical component library contains over 1,500 purified natural products and over 50,000 extracts/fractions from over 1,200 different plants</p> <p>It also provides new substrates for small molecule drug discovery.</p>
---	--

About HMPL-004

<ul style="list-style-type: none"> It is a novel, oral Inflammatory Bowel Disease (IBD) therapy that has shown a remarkable efficacy and safety profile in two Phase II trials for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). Its global Phase IIb UC clinical trial was highly successful, and the results were presented in a Distinguished Plenary oral presentation at Digestive Disease Week in May 2010. It is a proprietary botanical product that acts on multiple targets in the pathogenesis of inflammation. It is a compound extracted from a Chinese herb under controlled conditions and its composition is well characterised. The anti-inflammation activity of HMPL-004 was originally identified in a cell-based anti-inflammation screening assay at HMP More information on: http://www.hmplglobal.com/en
